AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 3,657 Shares

Posted by Stanley Muller on Sep 10th, 2026

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) insider Salvatore Privitera sold 3,657 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00. Following the sale, the insider directly owned 147,264 shares of the company’s stock, valued at $8,099,520. The trade was a 2.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Trading Down 0.2%

Shares of NASDAQ:ATRC traded down $0.10 during midday trading on Thursday, hitting $52.93. 121,522 shares of the stock traded hands, compared to its average volume of 800,797. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $41.54 and its two-hundred day moving average is $33.26. The stock has a market capitalization of $2.69 billion, a PE ratio of 252.07 and a beta of 1.26. AtriCure, Inc. has a one year low of $25.36 and a one year high of $55.72.

AtriCure (NASDAQ:ATRC – Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same period last year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC lifted its stake in shares of AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after buying an additional 1,230 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of AtriCure by 1.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after buying an additional 8,956 shares in the last quarter. Jane Street Group LLC grew its position in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after buying an additional 87,553 shares during the period. Finally, Strs Ohio purchased a new position in AtriCure during the 1st quarter valued at about $158,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Ratings Changes

ATRC has been the topic of several research analyst reports. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Piper Sandler raised their price target on AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Needham & Company LLC lifted their price target on shares of AtriCure from $45.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. UBS Group reduced their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $52.00.

Get Our Latest Research Report on ATRC

About AtriCure

(Get Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.